What serious risk is associated with the use of raloxifene for osteoporosis?

Raloxifene, a selective estrogen receptor modulator (SERM), is primarily used for the prevention and treatment of osteoporosis in postmenopausal women. One of the serious risks associated with its use is venous thrombosis, which includes conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). This risk arises because raloxifene has estrogen-like effects on certain tissues, which can increase the tendency of blood to clot.

It is important to monitor patients for signs of thromboembolic events, particularly in individuals who may already have risk factors, such as prolonged immobility, obesity, or a history of clotting disorders. By understanding this risk, healthcare providers can make informed decisions regarding the use of raloxifene and implement appropriate preventive measures when necessary.